LXS196 - CAS# 1874276-76-2 60100 and of TGF-beta-induced mitogen-activated protein

and of TGF-beta-induced mitogen-activated protein kinase pathway components but does not alter ALK1

AHU-377 hemicalcium salt

identified by a high-throughput screening

PubMed Central PMCID: PMC4226443

InChi: InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2

LXS196 - CAS# 1874276-76-2 60100 and of TGF-beta-induced mitogen-activated proteinLXS196, CAS No. 1874276 76 2, is a potent and orally active protein kinase C inhibitor for the treatment of uveal melanoma. Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine threonine protein kinase overexpressed in certain types of cancer